Tempest Therapeutics Extends Limited Duration Stockholder Rights Plan; Shares Rise Premarket

MT Newswires Live10-10

Tempest Therapeutics (TPST) said Thursday that its board approved an amendment to extend the company's limited duration stockholder rights plan until the annual shareholder meeting.

The company's trading price continues to "fundamentally undervalue" Tempest Therapeutics and the stockholder rights plan is put in place to help shareholders realize the long-term value of their stakes, said Tempest Chief Executive Officer Stephen Brady.

Tempest Therapeutics said the extension is not a response to a specific takeover threat and does not prevent its board from accepting acquisition proposals or engaging with interested parties.

Shares of the company rose more than 34% in recent premarket activity.

Price: 1.81, Change: +0.46, Percent Change: +34.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment